Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q8WUF8

UPID:
F172A_HUMAN

ALTERNATIVE NAMES:
Protein FAM172A

ALTERNATIVE UPACC:
Q8WUF8; B2R7C6; B4DJ14; B4DLG5; Q9H0U8

BACKGROUND:
The Cotranscriptional regulator FAM172A plays a crucial role in cellular biology by regulating alternative splicing through interactions with AGO2 and CHD7. This regulation is vital for maintaining the stability of protein-protein interactions at the chromatin-spliceosome interface. The potential hydrolase activity of FAM172A adds an additional layer to its functional repertoire, suggesting a broader impact on cellular metabolism.

THERAPEUTIC SIGNIFICANCE:
The exploration of Cotranscriptional regulator FAM172A's function offers promising avenues for drug discovery. Given its central role in the regulation of alternative splicing, targeting FAM172A could lead to innovative treatments for conditions where splicing plays a key role in disease pathology.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.